메뉴 건너뛰기




Volumn 13, Issue 6, 2014, Pages 678-684

Putting the value into biosimilar decision making. The judgment value criteria

Author keywords

Biosimilars; Decision process; Immunogenicity; Value chain; Value in health

Indexed keywords

BIOSIMILAR AGENT;

EID: 84896547976     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.01.051     Document Type: Review
Times cited : (19)

References (33)
  • 1
    • 78650589643 scopus 로고    scopus 로고
    • What is value in health care?
    • Porter M. What is value in health care?. NEJM 2010, 363(26):2477-2481.
    • (2010) NEJM , vol.363 , Issue.26 , pp. 2477-2481
    • Porter, M.1
  • 3
    • 84878544006 scopus 로고    scopus 로고
    • The impact of the profile of biologics on treatment costs
    • Leardini G., Rigon C. The impact of the profile of biologics on treatment costs. Autoimmun Rev 2013, 12(8):842-847.
    • (2013) Autoimmun Rev , vol.12 , Issue.8 , pp. 842-847
    • Leardini, G.1    Rigon, C.2
  • 4
    • 84878622273 scopus 로고    scopus 로고
    • Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?
    • Modena V., Bianchi G., Roccatello D. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?. Autoimmun Rev 2013, 12(8):835-838.
    • (2013) Autoimmun Rev , vol.12 , Issue.8 , pp. 835-838
    • Modena, V.1    Bianchi, G.2    Roccatello, D.3
  • 5
    • 84866846273 scopus 로고    scopus 로고
    • Biologic drugs in autoinflammatory syndromes
    • [Review]
    • Caorsi R., Federici S., Gattorno M. Biologic drugs in autoinflammatory syndromes. Autoimmun Rev 2012, 12(1):81-86. [Review].
    • (2012) Autoimmun Rev , vol.12 , Issue.1 , pp. 81-86
    • Caorsi, R.1    Federici, S.2    Gattorno, M.3
  • 6
    • 84874140621 scopus 로고    scopus 로고
    • Analytical and bioanalytical assay challenges to support comparability studies for biosimilar drug development
    • Xiao Yann C., Wake A., Gouty D. Analytical and bioanalytical assay challenges to support comparability studies for biosimilar drug development. Bioanalysis 2013, 5(5):517-520.
    • (2013) Bioanalysis , vol.5 , Issue.5 , pp. 517-520
    • Xiao Yann, C.1    Wake, A.2    Gouty, D.3
  • 7
    • 84886946831 scopus 로고    scopus 로고
    • Optimizing anti-TNF treatments in inflammatory bowel disease
    • Ben-Horin S., Kopylov U., Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2014, 13(1):24-30.
    • (2014) Autoimmun Rev , vol.13 , Issue.1 , pp. 24-30
    • Ben-Horin, S.1    Kopylov, U.2    Chowers, Y.3
  • 9
    • 70449686823 scopus 로고    scopus 로고
    • Avorn 1 J.Balancing innovation, access, and profits - market exclusivity for biologics
    • Engelberg A.B., Kesselheim A.S., Avorn 1 J. Balancing innovation, access, and profits - market exclusivity for biologics. N Engl J Med 2009, 361:1917-1919.
    • (2009) N Engl J Med , vol.361 , pp. 1917-1919
    • Engelberg, A.B.1    Kesselheim, A.S.2
  • 10
    • 84878558504 scopus 로고    scopus 로고
    • Novel diagnostic approaches and cost-benefit balance of treatment of immune-mediated and rare disease in the era of biologic drugs: lessons from the 15th Turin Congress on Immune Pathology and Orphan Disease
    • Roccatello D. Novel diagnostic approaches and cost-benefit balance of treatment of immune-mediated and rare disease in the era of biologic drugs: lessons from the 15th Turin Congress on Immune Pathology and Orphan Disease. Autoimmun Rev 2013, 12(8):793-795.
    • (2013) Autoimmun Rev , vol.12 , Issue.8 , pp. 793-795
    • Roccatello, D.1
  • 11
    • 33749345017 scopus 로고    scopus 로고
    • The market for follow-on biologics: how will it evolve?
    • Grabowski H., Cockburn I., Long G. The market for follow-on biologics: how will it evolve?. Health Aff (Millwood) 2006, 25:1291-1301.
    • (2006) Health Aff (Millwood) , vol.25 , pp. 1291-1301
    • Grabowski, H.1    Cockburn, I.2    Long, G.3
  • 12
    • 58349096713 scopus 로고    scopus 로고
    • Development and testing of a decision board to help clinicians present treatment options to lupus nephritis patients in Brazil
    • Abreu M.M., Gafni A., Ferraz M.B. Development and testing of a decision board to help clinicians present treatment options to lupus nephritis patients in Brazil. Arthritis Rheum 2009, 61:37-45.
    • (2009) Arthritis Rheum , vol.61 , pp. 37-45
    • Abreu, M.M.1    Gafni, A.2    Ferraz, M.B.3
  • 13
    • 84896544207 scopus 로고    scopus 로고
    • The cost of capital for early-stage biotechnology ventures
    • Harvard Business School Press, Cambridge, MA, G. Pisano (Ed.)
    • Cockburn I., Lerner J. The cost of capital for early-stage biotechnology ventures. Science business: the promise, the reality and the future of biotech 2006, 115. Harvard Business School Press, Cambridge, MA. G. Pisano (Ed.).
    • (2006) Science business: the promise, the reality and the future of biotech , pp. 115
    • Cockburn, I.1    Lerner, J.2
  • 14
    • 33748346673 scopus 로고    scopus 로고
    • The knowledge-value chain: a conceptual framework for knowledge translation in health
    • Landry R., Amara N., Pablos-Mendes A., Shademani R., Gold I. The knowledge-value chain: a conceptual framework for knowledge translation in health. Bull World Health Organ 2006, 84:597-602.
    • (2006) Bull World Health Organ , vol.84 , pp. 597-602
    • Landry, R.1    Amara, N.2    Pablos-Mendes, A.3    Shademani, R.4    Gold, I.5
  • 15
    • 84896544386 scopus 로고    scopus 로고
    • [accessed 8/27/13]
    • [accessed 8/27/13]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500144124.pdf.
  • 17
    • 84873679430 scopus 로고    scopus 로고
    • Biosimilars in rheumatology: the wind of change
    • Schneider C.K. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis March 2013, 72(3):315-318.
    • (2013) Ann Rheum Dis , vol.72 , Issue.3 , pp. 315-318
    • Schneider, C.K.1
  • 18
    • 55349105870 scopus 로고    scopus 로고
    • Typical pitfalls in applications for marketing authorization of biotechnological products in Europe
    • Schneider C.K., Schäffner-Dallmann G. Typical pitfalls in applications for marketing authorization of biotechnological products in Europe. Nat Rev Drug Discov 2008, 7:893-899.
    • (2008) Nat Rev Drug Discov , vol.7 , pp. 893-899
    • Schneider, C.K.1    Schäffner-Dallmann, G.2
  • 21
    • 84863435547 scopus 로고    scopus 로고
    • The advent of biosimilar therapies in rheumatology-"o brave new world"
    • Scheinberg M.A., Kay J. The advent of biosimilar therapies in rheumatology-"o brave new world". Nat Rev Rheumatol 2012, 8:430-436.
    • (2012) Nat Rev Rheumatol , vol.8 , pp. 430-436
    • Scheinberg, M.A.1    Kay, J.2
  • 22
    • 84987994885 scopus 로고    scopus 로고
    • Institute of Medicine National Academies Press, Washington, DC
    • Institute of Medicine Performance measurement: accelerating improvement 2006, National Academies Press, Washington, DC.
    • (2006) Performance measurement: accelerating improvement
  • 24
    • 84870242760 scopus 로고    scopus 로고
    • Biologic registries in rheumatology: lessons learned and expectations for the future
    • [Review]
    • Elkayam O., Pavelka K. Biologic registries in rheumatology: lessons learned and expectations for the future. Autoimmun Rev 2012, 12(2):329-336. [Review].
    • (2012) Autoimmun Rev , vol.12 , Issue.2 , pp. 329-336
    • Elkayam, O.1    Pavelka, K.2
  • 25
    • 45949108207 scopus 로고    scopus 로고
    • WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19-20 April 2007
    • Joung J., Robertson J.S., Griffiths E., Knezevic I. WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19-20 April 2007. Biologicals 2008, 36(4):269-276.
    • (2008) Biologicals , vol.36 , Issue.4 , pp. 269-276
    • Joung, J.1    Robertson, J.S.2    Griffiths, E.3    Knezevic, I.4
  • 29
    • 84896543744 scopus 로고    scopus 로고
    • [Accessed 12/10/13]
    • [Accessed 12/10/13]. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/06/WC500144941.pdf.
  • 30
    • 84896548506 scopus 로고    scopus 로고
    • [Accessed 8/27/13]
    • [Accessed 8/27/13]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.
  • 31
    • 84896543050 scopus 로고    scopus 로고
    • Similar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseases
    • Desanvicente-Celis Z., Caro-Moreno J., Enciso-Zuluaga M., Anaya J.M. Similar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseases. Biosimilars 2013, 3:1-17.
    • (2013) Biosimilars , vol.3 , pp. 1-17
    • Desanvicente-Celis, Z.1    Caro-Moreno, J.2    Enciso-Zuluaga, M.3    Anaya, J.M.4
  • 32
    • 84896549321 scopus 로고    scopus 로고
    • Available from, [Accessed October 26, 2013. Portuguese]
    • o 55 Available from, [Accessed October 26, 2013. Portuguese]. http://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2010/anexo/anexo_res0055_16_12_2010.pdf.
    • o 55
  • 33
    • 84873864303 scopus 로고    scopus 로고
    • Consideraciones Regulatorias sobre Productos Biológicos em Brasil
    • Araujo D.V. Consideraciones Regulatorias sobre Productos Biológicos em Brasil. Value Health Reg Issues 2012, 1:254-256.
    • (2012) Value Health Reg Issues , vol.1 , pp. 254-256
    • Araujo, D.V.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.